A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

• Status: Recruiting
• Trial end date: 2023-08-17
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the effect of itraconazole and carbamazepine on LY3537982 when administered as multiple doses by conducting the blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 11 and 15 days for part 1 and part 2, respectively, not including screening.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Loxo Oncology, Inc.
• Treatments: Carbamazepine; Itraconazole

Criteria

Inclusion Criteria:

• Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease

• Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion Criteria:

• Females who are lactating or of childbearing potential

• Clinically significant history of any drug sensitivity, drug allergy, or food allergy